Australian Gonococcal Surveillance Programme Annual Report, 2023
DOI:
https://doi.org/10.33321/cdi.2025.49.007Keywords:
antimicrobial resistance, disease surveillance, gonococcal infection, Neisseria gonorrhoeaeAbstract
The Australian Gonococcal Surveillance Programme (AGSP) has continuously monitored antimicrobial resistance in Neisseria gonorrhoeae for more than 40 years. In 2023, a total of 10,105 isolates from patients in the public and private sectors, in all jurisdictions, were tested for in vitro antimicrobial susceptibility by standardised methods. Nationally, in 2023, the AGSP captured antimicrobial susceptibility data for 25% of all gonococcal infection notifications.
The current treatment recommendation for gonorrhoea, for the majority of Australia, continues to be dual therapy with ceftriaxone and azithromycin. In 2023, of N. gonorrhoeae isolates tested, 0.22% (22/10,105) met the WHO criterion for ceftriaxone decreased susceptibility (DS), defined as a minimum inhibitory concentration (MIC) value ≥ 0.125 mg/L.
Resistance to azithromycin was reported in 4.5% of N. gonorrhoeae isolates, proportionally stable since 2019. There were 27 isolates (0.27%) with high-level resistance to azithromycin (MIC value ≥ 256 mg/L) reported in Australia: Victoria (13), New South Wales (11), non-remote Western Australia (2) and Queensland (1). This is the highest number ever detected and reported in a twelve-month period by the AGSP.
In 2023, penicillin resistance was found in 30.7% of gonococcal isolates, and ciprofloxacin resistance in 60.3%, although there was considerable variation by jurisdiction. In some remote settings, penicillin remains recommended as part of an empiric therapy strategy. However, in 2023, in remote Northern Territory, five penicillin-resistant isolates were reported; and in remote Western Australia, 14.1% of gonococcal isolates (10/71) were penicillin resistant. In addition, there were eight ciprofloxacin-resistant isolates reported from remote Northern Territory; ciprofloxacin resistance rates have increased in remote Western Australia (16/71; 22.5%). This increase in penicillin-resistant Neisseria gonorrhoeae in the Northern Territory has effected a change in gonococcal treatment recommendations.
Downloads
References
Lahra MM, George CR, Whiley DM. The Australian Gonococcal Surveillance Programme 1979–2017. Microbiol Aust. 2017;38(4):175–9. doi: https://doi.org/10.1071/MA17062.
Lahra MM, Martin I, Demczuk W, Jennison AV, Lee KI, Nakayama SI et al. Cooperative recognition of internationally disseminated ceftriaxone-resistant Neisseria gonorrhoeae strain. Emerg Infect Dis. 2018;24(4):735–40. doi: https://doi.org/10.3201/eid2404.171873.
Whiley DM, Jennison A, Pearson J, Lahra MM. Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin. Lancet Infect Dis. 2018; 18(7):717–8. doi: https://doi.org/10.1016/S1473-3099(18)30340-2.
European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia. [Internet.] Stockholm: ECDC; 7 May 2018. Available from: https://www.ecdc.europa.eu/en/publications-data/rapid-risk-assessment-extensively-drug-resistant-xdr-neisseria-gonorrhoeae-united.
Tapsall JW, Limnios EA, Murphy DM. Analysis of trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Australia, 1997–2006. J Antimicrob Chemother. 2008;61(1):150–5. doi: https://doi.org/10.1093/jac/dkm434.
Hanrahan JK, Hogan TR, Buckley C, Trembizki E, Mitchell H, Lau CL et al. Emergence and spread of ciprofloxacin-resistant Neisseria gonorrhoeae in New South Wales, Australia: lessons from history. J Antimicrob Chemother. 2019;74(8):2214–9. doi: https://doi.org/ 10.1093/jac/dkz182.
Armstrong BH, Limnios A, Lewis DA, Hogan T, Kundu R, Ray S et al. Is gentamicin a viable therapeutic option for treating resistant Neisseria gonorrhoeae in New South Wales? Commun Dis Intell (2018). 2021;45. doi: https://doi.org/10.33321/cdi.2021.45.12.
King J, McManus H, Kwon JA, Gray R, McGregor S, Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2023. Sydney: University of New South Wales, Kirby Institute; 2023. Available from: https://www.kirby.unsw.edu.au/sites/default/files/documents/Annual-Surveillance-Report-2023_STI.pdf.
Australian Government Department of Health and Aged Care. National Notifiable Diseases Surveillance System (NNDSS) data visualisation tool. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 14 December 2022. [Accessed on 13 March 2024.] Available from: https://www.health.gov.au/resources/apps-and-tools/national-notifiable-diseases-surveillance-system-nndss-data-visualisation-tool.
Northern Territory Government Department of Health (NT Health), Centre for Disease Control. Public Health Alert: Penicillinase-producing Neisseria gonorrhoeae (PPNG): changes treatment recommendations for gonorrhoea NT wide. Darwin: NT Health; 23 October 2023. Available from: https://health.nt.gov.au/__data/assets/pdf_file/0006/1288635/health-alert-penicillinase-producing-neisseria-gonorrhoeae-231023.pdf.
Lahra MM, Hogan TR, Armstrong BH, for the National Neisseria Network. Australian Gonococcal Surveillance Programme Annual Report, 2021. Commun Dis Intell (2018). 2022;46. doi: https://doi.org/10.33321/cdi.2022.46.52.
Tapsall J, World Health Organization (WHO) Anti-Infective Drug Resistance Surveillance and Containment Team. Antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2001. Available from: https://apps.who.int/iris/handle/10665/66963.
Goire N, Freeman K, Tapsall JW, Lambert SB, Nissen MD, Sloots TP et al. Enhancing gonococcal antimicrobial resistance surveillance: a real-time PCR assay for detection of penicillinase-producing Neisseria gonorrhoeae by use of noncultured clinical samples. J Clin Microbiol. 2011;49(2):513–8. doi: https://doi.org/10.1128/JCM.02024-10.
Speers DJ, Fisk RE, Goire N, Mak DB. Non-culture Neisseria gonorrhoeae molecular penicillinase production surveillance demonstrates the long-term success of empirical dual therapy and informs gonorrhoea management guidelines in a highly endemic setting. J Antimicrob Chemother. 2014;69(5):1243–7. doi: https://doi.org/10.1093/jac/dkt501.
World Health Organization (WHO). Global action plan to control the spread and impact of antimicrobial resistance in Neisseria gonorrhoeae. Geneva: WHO; 2012. Available from: https://apps.who.int/iris/handle/10665/44863.
Tapsall JW, Australian Gonococcal Surveillance Programme. Use of a quality assurance scheme in a long-term multicentric study of antibiotic susceptibility of Neisseria gonorrhoeae. Genitourin Med. 1990;66(1):8–13. doi: https://doi.org/10.1136/sti.66.1.8.
Australian Gonococcal Surveillance Programme (AGSP) annual reports 2008 to 2021. Available from: Australian Government Department of Health and Aged Care. Australian Gonococcal Surveillance Programme (AGSP) annual reports. [Webpage.] Canberra: Australian Government Department of Health and Aged Care; 2023. [Accessed on 19 March 2024.] https://www1.health.gov.au/internet/main/publishing.nsf/Content/cda-pubs-annlrpt-gonoanrep.htm.
van Hal SJ, Whiley DM, Le T, Ray S, Kundu RL, Kerr E et al. Rapid expansion of Neisseria gonorrhoeae ST-7827 clone in Australia, with variable ceftriaxone phenotype unexplained by genotype. J Antimicrob Chemother. 2023;78(9):2203–8. doi: https://doi.org/10.1093/jac/dkad221.
Lahra MM, van Hal SJ, Hogan TR, for the National Neisseria Network. Australian Gonococcal Surveillance Programme Annual Report, 2022. Commun Dis Intell (2018). 2023;47. doi: https://doi.org/10.33321/cdi.2023.47.45.
Unemo M, Tapsall JW, Ndowa F, Lewis DA. Meeting the public health challenge of multidrug -and extensively drug-resistant Neisseria gonorrhoeae. Expert Rev Anti Infect Ther. 2009;7(7):821–34. doi: https://doi.org/10.1586/eri.09.63.
Osnes MN, Didelot X, Korne-Elenbaas J, Alfsnes K, Brynildsrud OB, Syversen G et al. Sudden emergence of a Neisseria gonorrhoeae clade with reduced susceptibility to extended-spectrum cephalosporins, Norway. Microb Genom. 2020;6(12):mgen000480. doi: https://doi.org/10.1099/mgen.0.000480.
Day M, Pitt R, Mody N, Saunders J, Rai R, Nori A et al. Detection of 10 cases of ceftriaxone-resistant Neisseria gonorrhoeae in the United Kingdom, December 2021 to June 2022. Euro Surveill. 2022;27(46):2200803. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.46.2200803.
European Centre for Disease Prevention and Control (ECDC). Rapid risk assessment: extensively drug-resistant (XDR) Neisseria gonorrhoeae in the United Kingdom and Australia: 7 May 2018. Stockholm: ECDC; 7 May 2018. Available from: https://www.ecdc.europa.eu/sites/default/files/documents/RRA-Gonorrhoea,%20Antimicrobial%20resistance-United%20Kingdom,%20Australia.pdf.
Whiley DM, Jennison A, Pearson J, Lahra MM. Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin. Lancet Infect Dis. 2018;18(7):717–8. doi: https://doi.org/10.1016/S1473-3099(18)30340-2.
Jennison AV, Whiley D, Lahra MM, Graham RM, Cole MJ, Hughes G et al. Genetic relatedness of ceftriaxone-resistant and high-level azithromycin resistant Neisseria gonorrhoeae cases, United Kingdom and Australia, February to April 2018. Euro Surveill. 2019;24(8):1900118. doi: https://doi.org/10.2807/1560-7917.ES.2019.24.8.1900118.
Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S et al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill. 2022;27(24):2200455. doi: https://doi.org/10.2807/1560-7917.ES.2022.27.24.2200455.
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Communicable Diseases Intelligence
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
